India, December 08, 2022: National award-winning start-ups, Jackfruit365, the company behind the patented green jackfruit flour known for its proven efficacy to control blood sugar among persons with diabetes (PWD), and BeatO, a comprehensive digital care platform that provides easy solutions for controlling and managing diabetes, partnered to evaluate the efficacy of medical nutrition therapy (MNT) with Jackfruit365 green jackfruit flour combined with BeatO’s smartphone integrated connected care for Indian patients with diabetes. This study was published today at the International Diabetes Federation (IDF) Congress in Lisbon.
The study suggests that the incorporation of Jackfruit365 green jackfruit flour in medical nutrition therapy (MNT) combined with an online CDE (Certified Diabetes Educator) counseling triggered by real-time self-monitoring of blood glucose levels on BeatO app using a smartphone-connected glucometer significantly reduced average blood glucose levels in three weeks with higher efficacy in the higher HbA1c subgroup.
Green jackfruit flour has been reported to lower glycaemic load (GL) because of its high fiber, both soluble and insoluble, and lower carbohydrate and calorie content. Jackfruit365 green jackfruit flour used in medical nutrition therapy (MNT) along with pharmacological interventions led to a significant reduction in HbA1c levels and PPG (post prandial blood glucose), demonstrating its efficacy in MNT (medical nutrition therapy) in T2DM (type 2 diabetes mellitus) patients.
Mr. James Joseph, Founder, of Jackfruit365.com said, “Diabetes is a serious & rapidly growing health issue among the masses in India. There are more than 70 million people suffering from diabetes which is expected to rise to over 134 million by 2045. Partnering with BeatO has led us toward the digital revolution in diabetes care. This study with closely monitored BeatO’s smartphone-integrated connected care service demonstrates a reduction in average blood sugar level in just three weeks of consumption of green jackfruit flour. We are glad the scientific committee of IDF accepted our joint study to demonstrate the opportunity to combine MNT with green jackfruit flour with a more frequent and affordable smartphone-integrated monitoring of blood sugar levels with BeatO App. We commend BeatO for coming up with such an innovative, easy-to-use solution.”
A gold standard study on Jackfruit365 green jackfruit flour conducted at the Government Medical College, Srikakulam, Andhra Pradesh, India, has been published in American Diabetes Association and Nature group journals. BeatO’s real-world evidence-based studies have been published in global forums such as the prestigious American Diabetes Association (ADA), International Diabetes Federation (IDF), and the Advanced Technologies and Treatment for Diabetes (ATTD).
While this gold standard clinical study highlights the therapeutic potential of green jackfruit flour integration in everyday meals for persons with diabetes, the real-time monitoring of blood glucose in diabetics through the BeatO app during green jackfruit flour consumption has enabled both patients and healthcare professionals to experience the combined efficacy much faster. This study comprising 353 people has highlighted the potential of technology combined with intake of a clinically proven dietary ingredient in effectively monitoring and controlling blood sugar in individuals with diabetes.
Gautam Chopra, Co-Founder, and CEO of BeatO said, “My greatest source of satisfaction and motivation at work comes from hearing stories of our members, and how BeatO has helped improve their sugar levels, overall health, and quality of life. It’s heartening to see our users live better, healthier, and happier life because of the small changes they could make with BeatO. We keep customers at our core and persevere to build products according to their needs. Partnering with Jackfruit365 has paved way for an affordable diet solution to diabetes management for the masses; making the green jackfruit available in the form of flour for consumption round the year has opened avenues for the majority of the population to intake a healthy diet and clubbed with real-time self-monitoring, they can see the improvements and move towards an aspirational lifestyle.”
Dr. Mudit Sabharwal, Consultant Physician at BeatO talking about digital diabetes care said, “App-based connected care ecosystem for management of chronic conditions like diabetes helps with patient management and results in better health outcomes. BeatO is bridging barriers and has enabled doctors to track various biomarkers and make individualised precise treatment strategies for better outcomes. For patients, it has resulted in ease of monitoring their medical conditions and better compliance. Real-time glucose self-monitoring clubbed with an appropriate meal plan has reflected improvements in conditions of many BeatO users. With the incorporation of green jackfruit flour in the diet plan, the reduction in average blood glucose levels were seen in just three weeks. BeatO can facilitate the scaling of such a practice and contribute immensely towards prevention and management of diabetes.”
A multi-centric retrospective study of the digital medical records of uncontrolled DM (Diabetes Mellitus) patients (n=353) who had a smartphone-connected glucometer (SCG) (BeatO) for real-time monitoring of their blood glucose levels was conducted. The mean age of the subjects was 52.76±13.07 years, with a mean BMI of 26.46±4.93 kg/m2. These patients consumed Jackfruit365 green jackfruit flour (30g/day daily for 3 weeks, replacing an equal volume of rice or wheat flour) alongside pharmacological interventions and regular counseling by BeatO’s CDE (at least one session) for 3 weeks.
In the 3rd week of consumption, the average blood glucose levels significantly reduced from 185.4±68 to 151.1±80 (p <0.001) with a significant decrease (20.84%; p<0.002) in post-meal blood glucose levels, compared to one week before Jackfruit365 green jackfruit flour consumption. For the two subgroups (HbA1c>10% & HbA1c 8-10% at the week prior), a significantly higher reduction in average blood glucose was observed i.e. 223±103 to 175±101 (21.3%; p<0.002), in the high baseline HbA1c group, compared to 204±93 to 164±95 (19.4%; p<0.003), in the latter group. A similar higher reduction in HbA1c levels was also seen in the latter group (2.17% vs 1.01%), respectively. No new hypoglycaemic events were seen during the treatment period.